Optimizing adjuvant therapy for localized colon cancer and treatment selection in advanced colorectal cancer

Axel F Grothey, Alan P. Venook

Research output: Contribution to journalArticle

4 Scopus citations


Results from the pivotal IDEA trial, which evaluated 3 versus 6 months of adjuvant oxaliplatin-based chemotherapy, are incorporated into the NCCN Guidelines for Colon Cancer. The guidelines recommend that for patients with low-risk stage III disease, the preferred regimen is CAPEOX for 3 months or FOLFOX for 3 to 6 months. For patients with high-risk stage III disease, the preferred regimen is CAPEOX for 3 to 6 months or FOLFOX for 6 months. In metastatic disease, tumor sidedness should be a consideration when choosing a biologic. For BRAF-mutated disease, several triplets are now recommended options. Importantly, for a subset of patients with metastatic disease, new to the NCCN Guidelines is the incorporation of nivolumab and pembrolizumab as subsequent therapy for those with microsatellite instability-high or mismatch repair-deficient tumors.

Original languageEnglish (US)
Pages (from-to)611-615
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number5S
StatePublished - May 1 2018


ASJC Scopus subject areas

  • Oncology

Cite this